Dual targeting of GPX4 and TXNRD1 triggers eradication of AML cells through induction of apoptosis and ferroptosis

Abstract Myelodysplastic syndromes (MDS) are hematological disorders associated with bone marrow failure and abnormal hematopoietic cell growth, often progressing to acute myeloid leukemia (AML). Current treatments for AML and high-risk MDS are limited in efficacy, highlighting the need for new ther...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Cécile Favreau, Maxence Bourgoin, Coline Savy, Thomas Botton, Sarah Bailly, Florence Granger, Catherine Birck, Marwa Zerhouni, Emeline Kerreneur, Adele Rivault, Alban Vigroux, Jade Dussart-Gautheret, Marie-Laure Arcangeli, Arnaud Poterszman, Thomas Cluzeau, Stephane Rocchi, Arnaud Jacquel, Rachid Benhida, Patrick Auberger, Anthony R. Martin, Guillaume Robert
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2026-03-01
Serie:	Experimental Hematology & Oncology
Soggetti:	Acute myeloid leukemia Covalent inhibitor Targeted therapies GPX4 TXNRD1 Ferroptosis
Accesso online:	https://doi.org/10.1186/s40164-026-00766-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!